# A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C

> **NCT00940420** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 2695 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Copegus (ribavirin)
- **DRUG:** Copegus (ribavirin)
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00940420
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 2695 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940420, "A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00940420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*